Journal of the National Comprehensive Cancer Network : JNCCN
The most recent articles from:
J Natl Compr Canc Netw
-
The U. S. Food and Drug Administration facilitates the development of drugs intended to treat cancer and other serious or life-threatening diseases. ⋯ Drugs that receive priority review are agents that appear to represent significant improvements over existing therapies. A priority NDA is reviewed by the Agency within 6 months; a standard review is accomplished within 10 months. The Agency communicates with sponsors throughout the drug development process, suggesting appropriate trial designs and meaningful endpoints.